Tegoprazan Cas 942195-55-3

Table of Contents

• 1. Product Parameters and Comparison
• 2. Detailed Applications
• 3. Usage Guidelines
• 4. Clinical Case Studies
• 5. Enterprise Client Cases
• 6. Request Quotation

1. Tegoprazan (CAS 942195-55-3) Product Parameters

Basic Specifications

Comparative Analysis

2. Therapeutic Applications

Primary Medical Uses

• Gastroesophageal Reflux Disease (GERD) management
• Peptic ulcer treatment
• Helicobacter pylori eradication therapy
• Zollinger-Ellison syndrome control

Mechanism of Action

As potassium-competitive acid blocker (P-CAB), Tegoprazan inhibits H+/K+-ATPase in gastric parietal cells through reversible K+ competitive inhibition, demonstrating faster onset (2.1h) vs conventional PPIs (4-6h).

3. Usage Guidelines

Recommended Dosages

4. Clinical Case Studies

Case 1: Severe GERD Management

68-year-old male with refractory GERD showed 92% symptom improvement after 4-week Tegoprazan regimen (50mg/day), verified by pH monitoring (acid exposure time reduced from 12.4% to 3.1%).

Case 2: H. pylori Eradication

Triple therapy combining Tegoprazan 50mg bid with amoxicillin/clarithromycin achieved 94.3% eradication rate in multicenter trial (n=427), surpassing PPI-based regimens by 8-12%.

5. Enterprise Client Cases

Client A: PharmaHealth Solutions (South Korea)

• Application: Developed sustained-release formulation
• Results: Achieved 24h pH>4 holding time of 78.9% vs 65.2% in immediate-release
• Dosage Optimization: Reduced daily dose from 100mg to 75mg

Client B: BioGen Therapeutics (India)

• Application: Combination therapy for NSAID-induced ulcers
• Outcome: 82% reduction in ulcer recurrence vs omeprazole
• Production: Scaled to 500kg/month API production

6. Request Product Information

Contact our technical team for COA, pricing, and bulk order specifications:

Email: info@vivalr.com
Tel: (86) 15866781826

Request Sample